TY - JOUR
T1 - Change of regional choroid thickness after reduced-fluence photodynamic therapy for chronic central serous chorioretinopathy
AU - Manabe, Saki
AU - Shiragami, Chieko
AU - Hirooka, Kazuyuki
AU - Izumibata, Saeko
AU - Tsujikawa, Akitaka
AU - Shiraga, Fumio
N1 - Funding Information:
All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Financial Disclosures: Dr Shiragami received financial support from Bayer (Osaka, Japan) and Novartis (Tokyo, Japan); Dr Tsujikawa received financial support from Pfizer (Tokyo, Japan), Bayer (Osaka, Japan), Novartis (Tokyo, Japan), Santen (Osaka, Japan), Senju (Osaka, Japan), and Alcon (Tokyo, Japan); Dr Shiraga is a board member of Santen (Osaka, Japan) and a consultant of Bayer (Osaka, Japan), Novartis (Tokyo, Japan), Alcon (Tokyo, Japan), and Santen (Osaka, Japan); Dr Shiraga received financial support from Santen (Osaka, Japan), Novartis (Tokyo, Japan), Senju (Osaka, Japan), Alcon (Tokyo, Japan), Topcon (Tokyo, Japan), Chuo Sangyo (Nishinomiya, Japan), and Hoya (Tokyo, Japan). Funding/Support: Dr Hirooka received funding from a Grant-in-Aid for Scientific Research (No. 26462689 ) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (Tokyo, Japan); Dr Tsujikawa received funding from Pfizer (Tokyo, Japan), Bayer (Whippany, New Jersey, USA), Novartis (Tokyo, Japan), the Ministry of Health, Labour and Welfare , and Japan Society for the Promotion of Science (Tokyo, Japan); Dr Shiraga received funding from Santen (Osaka, Japan) and the Ministry of Health, Labour and Welfare, Japan (Tokyo, Japan). Contributions of authors: conception and design of the study (S.M., C.S.); analysis and interpretation (C.S., K.H., F.S.); writing of the article (S.M., C.S., A.T., F.S.); critical revision of the article (K.H., S.I., A.T.); final approval of the article (S.M., C.S., K.H., S.I., A.T., F.S.); data collection (S.M., C.S., S.I.); provision of patients (S.M., C.S.); statistical expertise (S.M., C.S., K.H., F.S.); obtaining funding (A.T.); literature search (S.M., C.S.); administrative support (C.S., K.H., F.S.).
Publisher Copyright:
© 2015 Elsevier Inc. All Rights Reserved.
PY - 2015/4/1
Y1 - 2015/4/1
N2 - Purpose To evaluate macular choroidal thickness after reduced-fluence photodynamic therapy (PDT) for chronic central serous chorioretinopathy (CSC). Design Prospective, consecutive, interventional case series. Methods Twenty-two eyes with chronic CSC were treated with reduced-fluence PDT. Macular choroidal thickness was examined using spectral-domain optical coherence tomography with a 3-dimensinonal radial scan protocol in the choroidal mode before and 1, 3, and 6 months after the treatment. The mean choroidal thickness in the Early Treatment Diabetic Retinopathy Study grid (center, inner circle, and outer circle) was compared between before and after therapy, as well as between treated eyes and 54 volunteer normal eyes. Results Chronic CSC eyes showed significantly thicker choroids in the macular area compared with normal controls (P <.0001). After the single treatment session, subretinal fluid resolved completely in all eyes, and there were no recurrences during the study period. Choroidal thickness within the center area and inner circle showed a significant reduction at all time points after treatment (P <.05). The choroidal thickness in the outer circle showed a statistically significant reduction at 1 and 3 months but not at 6 months. After treatment, the choroidal thickness reduced to the normal values at the center and inner circle, but was still significantly thicker in the outer circle (P <.01). Conclusion Chronic CSC eyes showed significantly thicker choroids in the macular area. After reduced-fluence PDT, macular choroidal thickness became thinner within 6 months of treatment.
AB - Purpose To evaluate macular choroidal thickness after reduced-fluence photodynamic therapy (PDT) for chronic central serous chorioretinopathy (CSC). Design Prospective, consecutive, interventional case series. Methods Twenty-two eyes with chronic CSC were treated with reduced-fluence PDT. Macular choroidal thickness was examined using spectral-domain optical coherence tomography with a 3-dimensinonal radial scan protocol in the choroidal mode before and 1, 3, and 6 months after the treatment. The mean choroidal thickness in the Early Treatment Diabetic Retinopathy Study grid (center, inner circle, and outer circle) was compared between before and after therapy, as well as between treated eyes and 54 volunteer normal eyes. Results Chronic CSC eyes showed significantly thicker choroids in the macular area compared with normal controls (P <.0001). After the single treatment session, subretinal fluid resolved completely in all eyes, and there were no recurrences during the study period. Choroidal thickness within the center area and inner circle showed a significant reduction at all time points after treatment (P <.05). The choroidal thickness in the outer circle showed a statistically significant reduction at 1 and 3 months but not at 6 months. After treatment, the choroidal thickness reduced to the normal values at the center and inner circle, but was still significantly thicker in the outer circle (P <.01). Conclusion Chronic CSC eyes showed significantly thicker choroids in the macular area. After reduced-fluence PDT, macular choroidal thickness became thinner within 6 months of treatment.
UR - http://www.scopus.com/inward/record.url?scp=84924865208&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84924865208&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2015.01.006
DO - 10.1016/j.ajo.2015.01.006
M3 - Article
C2 - 25595669
AN - SCOPUS:84924865208
SN - 0002-9394
VL - 159
SP - 644-651.e1
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
IS - 4
ER -
